Literature DB >> 29788338

Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.

Amy Hemperly1, William J Sandborn2, Niels Vande Casteele1,2.   

Abstract

This review describes the clinical pharmacology of the major drugs used for the treatment of patients with inflammatory bowel disease (IBD). Pharmacokinetics, drug metabolism, mechanism of action, efficacy, and safety profile are discussed. Some small molecules were developed to act systemically (eg, ozanimod) or locally (eg, aminosalicylates) and thus have disparate pharmacokinetic properties. In addition, locally acting compounds have been optimized to mitigate systemic exposure-eg, budesonide, which undergoes extensive first-pass metabolism-thereby reducing systemic bioavailability and side effects. Other small molecules such as thiopurines are precursors of their active metabolites and differences in genotype or phenotype of metabolizing enzymes may affect efficacy and safety, requiring therapeutic drug monitoring (TDM). Monoclonal antibodies (MAs) are large molecules administered parenterally, and their pharmacokinetics may be influenced not only by the general immunoglobulin (Ig) G metabolism and recycling pathways but also by antigen properties such as antigen distribution and antigen concentration. In addition, antibody structure, host factors, concurrent medications, and immunogenicity may contribute to the substantial inter- and intrapatient variability in drug exposure and response observed for MAs. Current guidelines recommend reactive TDM of tumor necrosis factor antagonists at the time of loss of response. Evidence for proactive TDM and for the role of TDM for biologics with a different mechanism of action is emerging. Although small molecules offer potential benefits over biologics with oral administration and lack of immunogenicity, there may be risk for more systemic side effects due to off-target binding. Understanding drug metabolism, pharmacokinetic characteristics, and mechanism of action are important in selecting the right drug at the right time at the right dose for patients with IBD.10.1093/ibd/izy189_video1izy189.video15786062223001.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29788338     DOI: 10.1093/ibd/izy189

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  8 in total

1.  Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Christopher Ma; Nicola R Panaccione; Tran M Nguyen; Leonardo Guizzetti; Claire E Parker; Isra M Hussein; Niels Vande Casteele; Reena Khanna; Parambir S Dulai; Siddharth Singh; Brian G Feagan; Vipul Jairath
Journal:  J Crohns Colitis       Date:  2019-09-19       Impact factor: 9.071

Review 2.  Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.

Authors:  Tamara Pérez-Jeldres; Manuel Alvarez-Lobos; Jesús Rivera-Nieves
Journal:  Drugs       Date:  2021-05-13       Impact factor: 11.431

Review 3.  Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases.

Authors:  Mehak Bassi; Siddharth Singh
Journal:  BioDrugs       Date:  2022-03-23       Impact factor: 7.744

Review 4.  Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.

Authors:  Pavine L C Lefevre; Niels Vande Casteele
Journal:  J Crohns Colitis       Date:  2020-08-01       Impact factor: 9.071

5.  Conjugation of Amisulpride, an Anti-Psychotic Agent, with 5-Aminosalicylic Acid via an Azo Bond Yields an Orally Active Mutual Prodrug against Rat Colitis.

Authors:  Wooseong Kim; Dayoon Kim; Seongkeun Jeong; Sanghyun Ju; Hanju Lee; Soojin Kim; Jin-Wook Yoo; In-Soo Yoon; Yunjin Jung
Journal:  Pharmaceutics       Date:  2019-11-07       Impact factor: 6.321

6.  Clinical and Histologic Remission in an Adult Crohn's Disease Patient Following the Specific Carbohydrate Diet and Its Impact on Healthcare Costs.

Authors:  Ali Arjomand; David L Suskind
Journal:  Cureus       Date:  2022-02-08

7.  Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia.

Authors:  Yazed AlRuthia; Othman Alharbi; Abdulrahman M Aljebreen; Nahla A Azzam; Majid A Almadi; Ohud H Bahari; Khalid A Almalki; Abdulaziz T Atham; Ahmed S Alanazi; Maria Saeed; Baraa HajkhderMullaissa; Mohammad Alsenaidy; Bander Balkhi
Journal:  Cost Eff Resour Alloc       Date:  2019-12-04

8.  Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients.

Authors:  Eun Sil Kim; Yiyoung Kwon; Yon Ho Choe; Mi Jin Kim
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.